Three cash-pay verticals dominate the modern clinic landscape: GLP-1 weight loss, HRT/TRT, and peptide therapy. All three operate outside insurance billing, charge recurring monthly fees, and serve populations that historically went undertreated. But the unit economics of each vertical are very different. Cost per inquiry, show rate, close rate, and lifetime value vary enough that picking the wrong one to start with can cost a clinic 6–12 months of growth.
This piece compares the three side by side, with practical numbers from live ad accounts, and lays out which vertical to start with based on where a clinic is in its growth cycle.
Vertical 1: GLP-1 Weight Loss
GLP-1 weight loss is the largest and most visible of the three verticals. Compounded semaglutide and tirzepatide programs have driven a massive expansion in patient demand since 2023, and most clinic owners are aware of the opportunity by now. The size of the market is the upside; the size of the competition is the downside.
Practical numbers for GLP-1 in 2026: cost per inquiry $20–$40 on Meta, cost per deposit-paid booking $50–$100, show rate 80–88% with deposit-gating, close rate 30–45% on the consultation, average patient LTV $2,400–$4,800 over 12–18 months. The economics work, but the friction is high: ad-policy compliance is strict (no drug brand names, no body-comparison imagery), audience saturation is real, and creative fatigue happens fast.
Vertical 2: HRT / TRT
HRT/TRT is the under-appreciated giant of cash-pay healthcare. The total addressable market is roughly 15 million men with low testosterone in the United States, and only a small fraction are currently treated. The audience is older, more financially stable, less price-sensitive, and far less paid-media saturated than weight loss.
Practical numbers for HRT/TRT in 2026: cost per inquiry $15–$30 on Meta (about 30% lower than GLP-1), cost per deposit-paid booking $40–$80, show rate 85–92% with deposit-gating (highest of the three verticals), close rate 35–50% on the consultation, average patient LTV $4,000–$10,000 over 18–36 months. The combination of lower acquisition cost and higher lifetime value gives HRT the strongest unit economics of the three.
Vertical 3: Peptide Therapy
Peptide therapy is the smallest of the three verticals but also the least competitive. The compounded peptide market is growing rapidly, and most clinics avoid marketing peptides because of the compliance burden. The clinics that do build a working funnel face very little ad inventory competition in their local market.
Practical numbers for peptide therapy in 2026. Cost per inquiry $35–$60 on Meta (roughly double GLP-1 and HRT), cost per deposit-paid booking $80–$150, show rate 78–85% with deposit-gating, close rate 30–45% on the consultation, average patient LTV $1,500–$6,000 depending on protocol. The unit economics require LegitScript verification ($1,995 application + $1,495/year), education-led creative, and a custom quiz funnel that handles medical specifics post-click. Higher CPL, more setup work, but defensible margin once it’s working.
Side-by-Side Comparison
At $2,000/month Meta spend over 90 days, the three verticals deliver roughly:
GLP-1 weight loss: 60–90 deposit-paid bookings · $50–$100 cost per booking · LTV $2,400–$4,800.
HRT/TRT: 75–110 deposit-paid bookings · $40–$80 cost per booking · LTV $4,000–$10,000.
Peptide therapy: 25–45 deposit-paid bookings · $80–$150 cost per booking · LTV $1,500–$6,000.
The order on raw bookings is HRT > GLP-1 > peptides. The order on lifetime ROI per acquired patient is HRT > GLP-1 > peptides as well, with HRT’s prospect compounded by its longer treatment duration. Peptides win on competitive moat (less competition, harder to dislodge once established) but lose on raw volume and acquisition efficiency.
“Everyone chases GLP-1 because it is in the headlines, but HRT quietly has the better math: lower acquisition cost and a patient who stays for years. If I were starting one vertical today, it would be hormones,” says Simon Molay, founder of ScaleClinics.
Which Vertical Should a Clinic Start With?
For most clinic owners launching paid acquisition for the first time, the right starting vertical is HRT/TRT. The CPL is the lowest, the show rate is the highest, the ad policy is the most forgiving, and the LTV math gives the most room for error while you learn what works. Most agencies default to GLP-1 because of the market attention, but the unit economics of HRT are objectively better in 2026.
There are exceptions. If the clinic already has a GLP-1 program in place and is just looking for a marketing system, start there because the operational fit matters more than the marginal advantage of HRT. If the clinic is building a peptide-led practice from scratch, do not start with peptides. Start with HRT, prove the funnel mechanics, complete LegitScript in parallel, and add peptides as the second vertical once the patient acquisition system is producing predictable results.
When to Add a Second Vertical
Most clinics should not run more than one vertical for the first 3–6 months. Splitting ad spend across multiple audiences slows Meta’s learning, dilutes creative testing, and adds operational complexity at exactly the wrong stage. The clean rule is to prove unit economics on one vertical, scale ad spend on it to $4,000–$5,000/month, and only then add the second vertical.
The right sequencing for most clinics is to start with HRT/TRT for 3–6 months, add GLP-1 weight loss as the second vertical, add peptides as the third vertical (after LegitScript verification clears, which can run in parallel during the first 6 months). Each new vertical opens a new audience without replacing the existing one, and the cumulative ad-account history makes each new vertical easier to launch than the last.
Common Mistakes in Multi-Vertical Marketing
The most common mistake clinics make in multi-vertical marketing is running all three verticals from day one. The instinct is “why not market everything we offer?” Each vertical needs its own creative, funnel, ad set, and learning period. Running them simultaneously means none of them get enough budget to exit Meta’s learning phase, and CPL stays elevated across the board.
Other recurring mistakes include using the same ad copy across verticals (different audiences respond to different framing), running a single shared funnel for all three verticals (each needs vertical-specific qualifying questions), and treating peptides like GLP-1 for compliance purposes (peptides require LegitScript, GLP-1 does not). The clinics that win at multi-vertical patient acquisition treat each vertical as its own discrete marketing program with its own funnel, creative library, and performance benchmarks.